Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLLSNASDAQ:SYNASDAQ:TILOTCMKTS:TRXDW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$1.47+2.1%$1.47$1.10▼$2.43$80.04M2.92142,894 shs32,669 shsSYSo-Young International$1.72+3.3%$0.91$0.66▼$2.24$168.39M1.01176,317 shs4.27 million shsTILInstil Bio$28.53-4.4%$21.92$9.62▼$92.00$195.72M2.27179,209 shs211,396 shsTRXDWTransEnterix$0.15$0.15$0.12▼$0.18$21.42M2.568,250 shsN/A2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis+2.08%+7.30%0.00%+13.08%-23.04%SYSo-Young International+3.31%+66.50%+101.76%+80.53%+60.30%TILInstil Bio-4.39%+2.44%+35.73%+58.59%+186.73%TRXDWTransEnterix0.00%0.00%0.00%0.00%+13,536.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLLSCellectis2.8426 of 5 stars3.55.00.00.00.02.50.6SYSo-Young International0.5366 of 5 stars1.03.00.00.01.50.80.6TILInstil Bio2.8438 of 5 stars3.52.00.00.02.23.30.6TRXDWTransEnterixN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLLSCellectis 3.00Buy$4.00172.11% UpsideSYSo-Young International 2.00Hold$0.80-53.35% DownsideTILInstil Bio 3.00Buy$119.00317.10% UpsideTRXDWTransEnterix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TRXDW, CLLS, TIL, and SY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$125.00 ➝ $125.006/2/2025TILInstil BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/22/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$110.00 ➝ $105.005/13/2025CLLSCellectisBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLLSCellectis$49.22M1.66N/AN/A$2.36 per share0.62SYSo-Young International$200.94M0.87$0.01 per share143.87$2.63 per share0.65TILInstil BioN/AN/AN/AN/A$25.96 per shareN/ATRXDWTransEnterix$8.53M2.51$0.11 per share1.40$2.68 per share0.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLLSCellectis-$36.76M-$0.86N/AN/AN/A-114.82%-62.55%-21.19%8/5/2025 (Estimated)SYSo-Young International-$80.76M-$0.80N/A∞N/A-41.03%-2.14%-1.61%8/20/2025 (Estimated)TILInstil Bio-$74.14M-$11.97N/AN/AN/AN/A-45.52%-29.23%8/12/2025 (Estimated)TRXDWTransEnterix-$154.20M-$4.22N/AN/AN/A-2,149.15%-83.74%-64.94%N/ALatest TRXDW, CLLS, TIL, and SY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/16/2025Q1 2025SYSo-Young International-$0.34-$0.04+$0.30-$0.04$293.76 million$40.95 million5/13/2025Q1 2025TILInstil Bio-$2.02-$4.32-$2.30-$4.32N/AN/A5/12/2025Q1 2025CLLSCellectis-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million3/28/2025Q4 2024SYSo-Young International$0.0906-$0.07-$0.1606-$0.81$402.58 million$50.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLLSCellectisN/AN/AN/AN/AN/ASYSo-Young InternationalN/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/AN/ATRXDWTransEnterixN/AN/AN/AN/AN/ALatest TRXDW, CLLS, TIL, and SY DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/28/2025SYSo-Young International--$0.02254/8/20254/8/20254/25/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLLSCellectis0.441.671.67SYSo-Young InternationalN/A2.752.45TILInstil Bio0.5830.3330.33TRXDWTransEnterix0.043.242.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLLSCellectis63.90%SYSo-Young International35.31%TILInstil Bio60.56%TRXDWTransEnterix8.22%Insider OwnershipCompanyInsider OwnershipCLLSCellectis16.41%SYSo-Young International16.70%TILInstil Bio46.50%TRXDWTransEnterix3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLLSCellectis29055.58 million46.46 millionOptionableSYSo-Young International1,800101.44 million84.50 millionNot OptionableTILInstil Bio4106.56 million3.51 millionNo DataTRXDWTransEnterixN/A142.78 millionN/ANot OptionableTRXDW, CLLS, TIL, and SY HeadlinesRecent News About These CompaniesLife Science Partners L P Synergy's Net WorthFebruary 9, 2024 | benzinga.comAsensus Surgical Inc (ASXC)January 30, 2024 | investing.comTransEnterix, Inc. (TRXDW)January 21, 2024 | ca.finance.yahoo.comSurgical Robots Global Market Report 2023June 13, 2023 | finance.yahoo.comAsensus Surgical (NYSEMKT: ASXC)May 27, 2023 | fool.comProfitable Strategic Report for the Robotic Endoscopy Devices Market with Business Strategies, Current Insight - openPRMay 12, 2023 | news.google.comAsia Pacific Minimally Invasive Gastrointestinal (GI) Surgical ... - Cottonwood Holladay JournalMay 12, 2023 | news.google.comGlobal Minimally Invasive Gastrointestinal (GI) Surgical Systems ... - Cottonwood Holladay JournalMay 12, 2023 | news.google.comAsensus Surgical, Inc. Reports Operating and Financial Results for ... - BenzingaMay 12, 2023 | news.google.comSurgical Robots Market 2023 is Booming Across the Globe by ... - Cottonwood Holladay JournalMay 11, 2023 | news.google.comBariatric Surgery Devices Market Size, Trends, Share, Growth and ... - Cottonwood Holladay JournalMay 11, 2023 | news.google.comSurgical Robots Market: The global market is expected to grow at a ... - Digital JournalMay 10, 2023 | news.google.comMinimally Invasive Gastrointestinal (GI) Surgical Systems Market ... - Digital JournalMay 10, 2023 | news.google.comSurgical Robots Market to Grow at Rapid Pace with Advancements ... - Digital JournalMay 10, 2023 | news.google.comMedical Intelligent Auxiliary Robot Market 2023 Competitive Insights ... - Cottonwood Holladay JournalMay 10, 2023 | news.google.comGlobal Healthcare Robotics-Surgical Robots Market 2023, CAGR ... - Cottonwood Holladay JournalMay 9, 2023 | news.google.comSurgical Robots Market Excellent CAGR of 18%, Growth, Industry ... - Digital JournalMay 8, 2023 | news.google.comExponential Growth Expected for Intelligent Tissue Autonomous Robots Market With Complete SWOT Analysis by For - openPRMay 8, 2023 | news.google.comObesity Surgery Device Market Research Report 2023-2031 Market ... - The Northwestern ExaminerMay 7, 2023 | news.google.comGlobal Surgical Robotics Market Insights Report 2022, Trends ... - FylladeyMay 5, 2023 | news.google.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAmong the Market’s Most Shorted: 2 Firms With +40% Short InterestBy Leo Miller | June 3, 2025View Among the Market’s Most Shorted: 2 Firms With +40% Short Interest3 Stocks Getting Rare Double Upgrades From AnalystsBy Chris Markoch | June 6, 2025View 3 Stocks Getting Rare Double Upgrades From AnalystsAST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!By Thomas Hughes | June 16, 2025View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!Breakout Momentum Plays You May Not Know AboutBy Nathan Reiff | June 6, 2025View Breakout Momentum Plays You May Not Know AboutSoundHound’s AI Growth Story Is Just Getting StartedBy Gabriel Osorio-Mazilli | June 16, 2025View SoundHound’s AI Growth Story Is Just Getting StartedTRXDW, CLLS, TIL, and SY Company DescriptionsCellectis NASDAQ:CLLS$1.47 +0.03 (+2.08%) As of 06/24/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.So-Young International NASDAQ:SY$1.72 +0.06 (+3.31%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$1.72 0.00 (0.00%) As of 04:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.So-Young International Inc. operates an online platform for consumption healthcare services in the People's Republic of China. The company offers So-Young Mobile App that offers users medical aesthetic knowledge and experience to reach an informed medical aesthetic treatment decision and make reservations for treatment with medical professionals and medical aesthetic institutions; So-Young Beauty which provides similar interfaces and functions as the mobile app, as well as serves as additional access points to the platform; and medical aesthetic community content through its website soyoung.com. It provides content in various media formats on its online platform generated by users, including professional generated, content from in-house editorial team that shares opinions on specific new medical procedures and trends; user generated content comprising Beauty Diaries that provides details about medical institution, doctor, price, and other information on the treatment; professional user generated, contents from the medical aesthetic influencers; and doctor generated, content from doctors to generate knowledge. In addition, the company offers consumption healthcare services, including dermatology, dentistry and orthodontics, physical examinations, gynecology, and postnatal care; reservation services; and software as a service. Further, it engages in research and development, production, sales, and agency of laser and other optoelectronic medical beauty equipment; manufacture and sells light therapy device, surgical laser device and other equipment; internet information and technology advisory; online medical treatment and consultation; management consulting; internet culture; micro finance services, as well as sells cosmetics products. The company was founded in 2013 and is headquartered in Beijing, China.Instil Bio NASDAQ:TIL$28.53 -1.31 (-4.39%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$29.27 +0.74 (+2.59%) As of 04:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.TransEnterix OTCMKTS:TRXDW$0.15 0.00 (0.00%) As of 03/7/2025TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
